Third Pole Therapeutics, which is developing an inhaled nitric oxide (iNO) generator, has announced a strategic collaboration agreement with Actelion Pharmaceuticals. Details of the agreement were not specified. Third Pole’s iNO platform is designed for more convenient delivery than the compressed gas cylinders currently in use.
The Third Pole device is primarily designed to produce NO for delivery to the lungs of premature babies in respiratory failure due to pulmonary hypertension. Actelion, which was acquired by Johnson & Johnson in 2017, specializes in the development of drugs for the treatment of pulmonary arterial hypertension, including Ventavis iloprost inhalation solution.
Third Pole Therapeutics founder and CEO David Zapol commented, “A strategic collaboration with the largest healthcare company in the world will ultimately benefit patients. Third Pole’s relationship with Johnson & Johnson began in May 2017 when our team won the Johnson & Johnson Innovation – JLABS @ M2D2 QuickFire Challenge. Our relationship has been fruitful, in part because of our shared belief that the future of healthcare is about finding the best solutions for patients and caregivers. Their unique capabilities make them an ideal strategic partner for our disruptive iNO platform technology.”
Read the Third Pole Therapeutics press release.
